Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...
MyChesCo on MSN3h
Faeth Therapeutics and GOG Foundation Launch Pioneering Phase 2 Trial for Advanced Endometrial Cancer
AUSTIN, TX & PHILADELPHIA, PA — Faeth Therapeutics and The GOG Foundation, Inc. have announced a significant milestone in the ...
Clinical Trials Arena on MSN2d
BioCity and MSD to evaluate cancer treatment combination in Phase I/II trial
BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...
The Manila Times3d
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Nuvectis Pharma, Inc. ("Nuvectis”, "Company”), a biopharmaceutical company focused on the development of innovative precision ...
Le Lézard4d
YourChoice Therapeutics Announces Nature Publication
YourChoice Therapeutics, Inc., pioneering hormone-free family planning products, announced today that Communications Medicine, a Nature Portfolio journal, has published a peer-reviewed paper on the ...
First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab
Open label study in forty AML and MDS patientsStudy financed by the US Department of DefenseCantargia (Cantargia AB; Nasdaq Stockholm:CANTA) ...
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the ...
Cantargia's TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited
TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB); ...
SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...
The Bakersfield Californian10d
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose ...
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to ...
Fierce Biotech10d
Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
American Association of Individual Investors10d
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Up 12.68%
Nuvectis Pharma, Inc.’s NVCT share price has surged by 12.68%, which has investors questioning if this is right time to sell.